Dicerna Pharmaceuticals Garners $25,000,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=00d5c047-0394-48cb-89fd-08f14c82ec83&Preview=1 -
Date
8/11/2010 -
Company Name
Dicerna Pharmaceuticals -
Mailing Address
480 Arsenal Street Building 1 Watertown, MA 02472 -
Company Description
Dicerna Pharmaceuticals is a venture-backed startup developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism. -
Website
http://www.dicerna.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Proceeds from the financing will be used to advance Dicerna’s lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the proceeds to continue to develop conjugated drug delivery systems, which combine Dicerna’s DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies, potentially allowing for direct delivery into specific cells of interest. -
M&A Terms
-
Venture Investor
Domain Associates -
Venture Investor
Oxford Bioscience Partners -
Venture Investor
Abingworth Management Inc -
Venture Investor
Skyline Ventures
